Rheumatoid arthritis

Where the papers sit

10 papers from the last 6 months study rheumatoid arthritis directly · updated from PubMed 1 Nov 2026

• Clinical Analytics in Rheumatology

  Data-driven rheumatology is expanding from diagnostic support to cost analysis and population-level risk profiling. Multimodal AI is being tested for fibromyalgia diagnostic delay, with reported sensitivity, specificity and accuracy, while other work maps AI adoption across the field. Economic studies emphasize drug reimbursement and treatment costs, and NHANES analysis links visceral adiposity with rheumatoid arthritis. These strands share an emphasis on measurable clinical and health-system signals rather than a single therapeutic intervention.

  4 papers · 40%

• Autoimmune Drug Delivery

  Nanoemulsions and other targeted carriers are being used to improve delivery of anti-inflammatory agents for chronic autoimmune disease. Rosuvastatin nanoemulgel and Huangqi Guizhi Wuwu decoction are assessed through dose-response and mechanistic studies rather than established clinical outcomes. Proinflammatory cytokines and tissue inflammation recur as efficacy readouts, with skin delivery appearing in the rosuvastatin work. Translation from animal or formulation studies to safe human dosing remains unresolved.

  3 papers · 30%

• Biomarkers and Emerging Therapies

  Flare prediction is moving toward integrated serum proteomics and autoantibody signatures to guide biologic tapering. Real-world studies continue to define the effectiveness and safety of Janus Kinase inhibitors, alongside CRP and VSIG4-related activity measures. Catalase-like nanozymes represent an experimental route to dampen oxidative and inflammatory injury. Validation across cohorts and comparison with established biologics remain open.

  3 papers · 30%